A rolling submission of a BLA for OST-HER2 has been initiated, seeking approval of the agent for the prevention or delay of recurrence in patients with fully resected pulmonary metastatic osteosarcoma #scmsm #oncology www.onclive.com/view/rolling...

@foxchasecancer.bsky.social Study Finds Radiation Therapy Administered Before Surgery Rarely Shrinks Retroperitoneal Sarcoma Tumors
#scmsm #oncology
www.onclive.com/view/study-f...

Legubicin More Than Doubles PFS in Advanced Soft Tissue Sarcoma
#scmsm #onvcology
www.onclive.com/view/legubic...

Toripalimab Plus Chidamide Yields Promising Efficacy in Advanced Sarcoma
#scmsm #oncology
www.onclive.com/view/toripal...

Global BOOM Report Highlights Need to Standardize Infection Management After Limb Salvage Surgery in Orthopedic Oncology | OncLive R. Lor Randall, MD, FACS, discusses global variation in DAIR strategies for post limb salvage infections, highlighting needs for standardization and multidisciplinary coordination.

Global BOOM Report Highlights Need to Standardize Infection Management After Limb Salvage Surgery in Orthopedic Oncology
#scmsm #oncology @ucdaviscancer.bsky.social
www.onclive.com/view/global-...

China’s NMPA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor | OncLive The NMPA of China has approved pimicotinib, a CSF-1R inhibitor, for the treatment of adults with symptomatic TGCT.

China’s NMPA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
#scmsm #oncology
www.onclive.com/view/china-s...

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology | OncLive Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology #bcsm #scmsm #hncsm
www.onclive.com/view/onclive...

Challenges in comparing checkpoint inhibitors in various sarcoma subtypes - VJOncology Nadia Hindi, MD, Fundación Jimenez Diaz University Hospital, Madrid, Spain, comments on the limitations of comparing immune checkpoint inhibitors in...

🎥Nadia Hindi, MD, highlights challenges in comparing ICIs vs antiangiogenic therapy in ultra-rare sarcomas. Limited data & lack of pure monotherapy cohorts make conclusions difficult—randomized trials are needed:

➡️https://buff.ly/utlNO0r⬅️

@ascocancer.bsky.social #ASCO25 #ImmunoOnc #scmSM

MRI and Ultrasound May Be Best Used in Tandem for Surveillance Imaging in Soft Tissue Sarcoma Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?

MRI and Ultrasound May Be Best Used in Tandem for Surveillance Imaging in Soft Tissue Sarcoma @rlrandallmd.bsky.social @ucdavis.bsky.social #scmsm #oncology
www.onclive.com/view/mri-and...

Imatinib Remains Standard of Care in GIST With ‘a Long Way to Go’ @cucancercenter.bsky.social #scmsm #oncology
www.onclive.com/view/imatini...

Nirogacestat Provides Long-Term Benefits in Desmoid Tumors Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.

Nirogacestat Provides Long-Term Benefits in Desmoid Tumors @myesmo.bsky.social #ESMORareCancers25 #scmsm #oncology
www.onclive.com/view/nirogac...

SON-1010 Plus Trabectedin Completes First Safety Review in Advanced Leiomyosarcoma/Liposarcoma Findings from the safety review of SON-1010 plus trabectedin in patients with advanced leiomyosarcoma or liposarcoma were positive.

SON-1010 Plus Trabectedin Completes First Safety Review in Advanced Leiomyosarcoma/Liposarcoma #scmsm #oncology
www.onclive.com/view/son-101...

Bioengineered Bone Marrow Model Reveals Potential New Strategies for Osteosarcoma Metastasis Control R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

Bioengineered Bone Marrow Model Reveals Potential New Strategies for Osteosarcoma Metastasis Control @rlrandallmd.bsky.social @ucdavis.bsky.social #scmsm #oncology
www.onclive.com/view/bioengi...

Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma The long-acting IL-7 agent efineptakin alfa was tolerable and led to responses in patients with Kaposi sarcoma, including in HIV-associated disease.

Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma
#scmsm #oncology #MedEd
onclive.com/view/efinept...

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma The FDA granted breakthrough therapy designation to lete-cel for patients with unresectable or metastatic myxoid/round cell liposarcoma.

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma
@fda.gov #scmsm #Oncology
www.onclive.com/view/lete-ce...

OST-HER2 Meets Primary End Point of Phase 2b Trial in Lung-Only Metastatic Osteosarcoma OST-HER2 shows promise in patients with recurrent, fully resected lung-only metastatic osteosarcoma.

OST-HER2 Meets Primary End Point of Phase 2b Trial in Lung-Only Metastatic Osteosarcoma
#scmsm #oncology #MedEd
www.onclive.com/view/ost-her...